NuVasive Tops Earnings Expectations, but Challenges Remain

NuVasive just topped earnings expectations in terms of top- and bottom-line growth, but it could still be tripped up by slowing revenue growth and litigation costs.

Apr 30, 2014 at 6:30PM

NuVasive (NASDAQ:NUVA), a maker of minimally invasive surgical products and biologics for spinal surgery, reported its first-quarter earnings on April 29.

NuVasive reported non-GAAP earnings of $14.3 million, or $0.29 per share, topping the Thomson Reuters consensus estimate of $0.23 per share. On a GAAP-adjusted basis, it posted a loss of $0.40 per share due to litigation expenses. NuVasive's revenue climbed 11% to $177.5 million, also topping the consensus estimate of $171.3 million.

Looking ahead to the full year, NuVasive expects non-GAAP earnings of $1.06 per share on revenue of $725 million, which misses analysts' expectations of $1.08 per share on revenue of $727.8 million. Yet shares of NuVasive, which have already rallied more than 65% over the past 12 months, still climbed 3% after the earnings announcement.

Does NuVasive still have room to run, or are its much larger rivals -- Stryker (NYSE:SYK), Zimmer Holdings (NYSE:ZMH), and Medtronic (NYSE:MDT) -- better investments?

How NuVasive is different from its rivals
At first glance, NuVasive looks comparable to Stryker, Zimmer, and Medtronic since they all sell spinal care products. Medtronic controls 36% of that market, followed by Johnson & Johnson's (NYSE: JNJ) 26% share, and Stryker's 9% share. NuVasive and Zimmer, respectively, control 5% and 3% of the market.

But while other companies mainly sell a wider variety of spinal products, NuVasive's business centers around a minimally invasive platform known as MAS (Maximum Access Surgery). MAS allows procedures such as a lateral entry approach known as XLIF -- which accesses the patient's spine through the side -- to be performed.

XLIF offers several key advantages over traditional procedures. The XLIF procedure takes as little as one hour to complete, compared to up to five hours for a traditional one. XLIF patients can typically recover within six weeks, compared to six months for traditional methods. As a result, post-operative pain is reduced, scars are minimal, and hospital stays are shortened.

The road to $1 billion
NuVasive estimates that the number of minimally invasive spine surgeries could climb from 25% of all spine procedures in 2014 to 80% by 2021. However, the overall market for spine procedures is only expected to grow at a compound annual growth rate (CAGR) of 4% to $8.7 billion by 2018, according to Research and Markets.

Nonetheless, the opportunity to grow within that market has led NuVasive to declare that it can eventually generate $1 billion in annual revenue. Unfortunately, NuVasive's year-over-year revenue growth has actually slowed down considerably over the past five years:

Fiscal Year

2009

2010

2011

2012

2013

Revenue

$370 million

$478 million

$541 million

$620 million

$685 million

Growth (YOY)

48%

29%

13%

15%

10%

Source: NuVasive annual reports.

Even if NuVasive meets its full-year forecast of $725 million for 2014, that would only represent under 6% growth from 2013. As a result, the road to $1 billion seems to be getting longer every year.

Quarterly growth tells a similar tale
When we look back at NuVasive's earnings and revenue growth over the past four quarters, we see similar problems -- slow earnings and revenue growth:

Quarter

GAAP EPS

Non-GAAP EPS

Revenue/Growth (YOY)

Non-GAAP Operating Margin

Q2 2013

($0.15)

$0.20

$165.7 million / 7.3%

14%

Q3 2013

$0.16

$0.39

$169.2 million / 14%

15.4%

Q4 2013

$0.13

$0.37

$190.8 million / 15.1%

16.3%

Q1 2014

($0.40)

$0.29

$177.5 million / 11.3%

13.2%

Source: NuVasive quarterly earnings.

That big plunge in GAAP EPS during the first quarter was mainly due to more than $30 million in litigation expenses, due to a trademark dispute with Neurovision Medical Products and a royalty dispute with Medtronic. Despite those problems, NuVasive continues to post stronger revenue growth than its larger peers, which all reported anemic growth in spinal products revenue last quarter. 

Company

Spine Business Revenue (Most Recent Quarter)

Growth (YOY)

Stryker

$177 million

0.7%

Zimmer Holdings

$48 million

1%

Medtronic

$744 million

(1%)

Source: Company quarterly earnings.

That disparity indicates that the market for minimally invasive spinal procedures is still growing, although the overall market growth of spinal products remains flat.

The Foolish fundamentals
Last but not least, we should also compare NuVasive's longer-term fundamentals to Stryker, Zimmer Holdings, and Medtronic.

Company

Market Cap

5-Year Price

Forward P/E (2015)

5-Year PEG

NuVasive

$1.6 billion

(9%)

24.4

3.0

Stryker

$29.4 billion

102%

14.7

1.8

Zimmer Holdings

$16.6 billion

119%

14.9

1.9

Medtronic

$58.9 billion

27%

14.4

2.4

Advantage

 

Zimmer

Medtronic

Stryker

Source: Yahoo! Finance, April 30.

NuVasive's stock has underperformed those of Stryker, Zimmer, and Medtronic over the past five years. Yet NuVasive still trades at a premium to all three in terms of its forward P/E and five-year PEG ratios.

The Foolish takeaway
It's certainly a positive sign that NuVasive topped earnings expectations. However, it's hard to see that optimism lasting very long, considering that NuVasive's revenue growth has slowed substantially, its bottom down is weighed down by litigation, and it is trading at a premium to its larger industry rivals despite increasingly low expectations for future earnings growth.

Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It recommends NuVasive and owns shares of Medtronic and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers